Overview
Affidea is a multinational healthcare provider offering diagnostic imaging, outpatient care, and cancer treatment mainly in Europe. It operates imaging centers and clinics that perform scans and deliver cancer care, using AI-powered imaging and digital tools to speed diagnoses, coordinate care, and improve workflows. It differentiates itself by the size of its European network and its high radiology accreditation, along with a strategy of acquisitions and partnerships that connect public and private healthcare systems. Its goal is to broaden access to high-quality imaging and cancer care by expanding through acquisitions and partnerships across Europe.
Work here?Claim your company
Simplify's take
What believers are saying
- Affidea's 23 July 2026 LIPS partnership accelerates UK access to specialist private care.
- Uroviva added prostate pathways on 3 April 2025, expanding Switzerland's oncology funnel.
- AI breast-imaging partnerships in 2025-2026 shorten reads and support higher throughput, lower labor pressure.
What critics are saying
- Affidea transferred Hungary operations to Medicare Group on 16 April 2026, signaling portfolio strain.
- Integrating Uroviva, LabPoint, and Berner Urologen risks clinician churn and delayed synergies.
- If private-pay imaging weakens, Affidea's acquisition-driven model loses cash for continued expansion.
What makes Affidea unique
- Affidea builds end-to-end cancer pathways by combining imaging, pathology, urology, and oncology.
- Switzerland now spans 39 centres and 12 laboratories after Uroviva and LabPoint deals.
- Affidea paired breast imaging with b-rayZ and Biotronics3D at RSNA 2025.
Help us improve and share your feedback! Did you find this helpful?